pediatric-onset multiple sclerosis

Study Shows Tysabri Reduces Risk of Cognitive Decline for Pediatric-Onset Multiple Sclerosis Patients

Post author:Trudy Horsting
Post published:October 25, 2019
Post category:Multiple Sclerosis

The Gap Tysabri is a therapy that has shown efficacy for reducing disease activity in patients diagnosed with pediatric-onset multiple sclerosis (POMS). Previous investigations have indicated that up to 58%…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More